Keybanc analyst Todd Fowler downgrades FedEx (NYSE:FDX) from Overweight to Sector Weight.
Biodexa Reports 12 Month Survival In MAGIC-G1 Study Of MTX110 In Recurrent Glioblastoma Patients
Biodexa Pharmaceuticals PLCBiodexa Reports 12 Month Survival in MAGIC-G1 Studyof MTX110 in Recurrent Glioblastoma PatientsCARDIFF, United Kingdom, February 8, 2024 (GLOBE NEWSWIRE) -- Biodexa Pharmaceuticals PLC